Antikoagulation und Antidote

Die demografische Entwicklung lässt erwarten, dass Mitarbeiter im Rettungsdienst und in der Notaufnahme immer häufiger mit Patienten unter Antikoagulationstherapie konfrontiert sein werden. Dieser Beitrag stellt den aktuellen Entwicklungsstand in der Prophylaxe und Therapie von Blutungskomplikationen bei bestehender oraler Antikoagulation dar.

• Literatur

• 1 Koscielny J, Ziemer S, von Heymann C. Patienten unter oraler Antikoagulation – Perioperatives Bridging. Hämostaseologie 2009; 29: 247-255
• 2 Haug M. Merkwürdige Geschichten rund um die Entdeckung und Entwicklung herkömmlicher Antithrombotika. Phlebologie 2014; 43: 93-98
• 3 Harbrecht U. Alte und neue Antikoagulanzien. Hämostaseologie 2011; 31: 21
• 4 Barthels M, Tiede A, Alban S. et al. Hämostaseologische Arzneimittel. In: Barthels M. Hrsg. Das Gerinnungskompendium. 2., vollständig überarbeitete und erweiterte Aufl. Stuttgart: Thieme; 2013: 844-1026
• 5 Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thrombosis Thrombolysis 2011; 31: 326-343
• 6 Wittkowsky AK, Devine EB. Frequency and causes of overanticoagulation and underanticoagulation in patients treated with warfarin. Pharmacother J Human Pharmacol Drug Ther 2004; 24: 1311-1316
• 7 Schmiedl S, Rottenkolber M, Szymanski J. et al. Blutungskomplikationen und Leberschädigungen unter Phenprocoumon. Dtsch Ärztebl Int 2013; 110: 523-524
• 8 Siguret V, Pautas E, Gouin-Thibault I. Warfarin therapy: influence of pharmacogenetic and environmental factors on the anticoagulant response to warfarin. Vitam Horm 2008; 78: 247-264
• 9 Lazo-Langner A, Kovacs MJ. Predicting warfarin dose. Curr Opin Pulmon Med 2010; 16: 426-431
• 10 Vahanian A, Alfieri O, Andreotti F. et al. Guidelines on the management of valvular heart disease (version 2012). The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2012; 33: 2451-2496
• 11 Heidbuchel H, Verhamme P, Alings M. et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. Eur Heart J 2016;
• 12 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. NEJM 2009; 361: 1139-1151
• 13 Giugliano RP, Ruff CT, Braunwald E. et al. Edoxaban versus warfarin in patients with atrial fibrillation. NEJM 2013; 369: 2093-2104
• 14 Granger CB, Alexander JH, McMurray JJ. et al. Apixaban versus warfarin in patients with atrial fibrillation. NEJM 2011; 365: 981-992
• 15 Patel MR, Mahaffey KW, Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. NEJM 2011; 365: 883-891
• 16 Nutescu EA, Burnett A, Fanikos J. et al. Pharmacology of anticoagulants used in the treatment of venous thromboembolism. J Thromb Thrombolysis 2016; 41: 15-31
• 17 Larsen TB, Skjoth F, Nielsen PB. et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 2016; 353: i3189
• 18 Ruff CT, Giugliano RP, Braunwald E. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955-962
• 19 Heim MU. Die neuen Querschnitts-Leitlinien der Bundesärztekammer – Evidenz-basierte Empfehlungen für die Risiko-Nutzen-Abwägung bei der Hämotherapie. AINS 2009; 44: 186-199
• 20 Ruff CT, Giugliano RP, Antman EM. Management of bleeding with non-vitamin k antagonist oral anticoagulants in the era of specific reversal agents. Circulation 2016; 134: 248-261
• 21 Schiele F, van Ryn J, Canada K. et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013; 121: 3554-3562
• 22 Glund S, Moschetti V, Norris S. et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost 2015; 113: 943-951
• 23 Pollack jr. CV, Reilly PA, Eikelboom J. et al. Idarucizumab for dabigatran reversal. NEJM 2015; 373: 511-520
• 24 Glund S, Stangier J, van Ryn J. et al. Effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase Ib study. Clin Pharmacokinet 2017; 56: 41-54
• 25 Pollack jr. CV, Reilly PA, Eikelboom J. et al. Idarucizumab for dabigatran reversal: updated results of the RE-VERSE AD study. Presented on 15 November at the American Heart Association (AHA) Scientific Sessions 2016, New Orleans, Louisiana.
• 26 Lu G, DeGuzman FR, Hollenbach SJ. et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013; 19: 446-451
• 27 Siegal DM, Curnutte JT, Connolly SJ. et al. Andexanet alfa for the reversal of factor Xa inhibitor Activity. NEJM 2015; 373: 2413-2424
• 28 Cohen AT, Harrington RA, Goldhaber SZ. et al. Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. NEJM 2016; 375: 534-544
• 29 Connolly SJ, Milling jr. TJ, Eikelboom JW. et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. NEJM 2016; 375: 1131-1141
• 30 Ansell JE, Bakhru SH, Laulicht BE. et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. NEJM 2014; 371: 2141-2142
• 31 Ansell JE, Laulicht BE, Bakhru SH. et al. Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin. Thromb Res 2016; 146: 113-118
• 32 Camm AJ, Lip GY, De Caterina R. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747
• 33 Hart RG, Eikelboom JW, Ingram AJ. et al. Anticoagulants in atrial fibrillation patients with chronic kidney disease. Nat Rev Nephrol 2012; 8: 569-578
• 34 Steiner T, Bohm M, Dichgans M. et al. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol 2013; 102: 399-412
• 35 Spahn DR, Borgeat A, Kern C. et al. Anwendung von Apixaban Guidelines der Expertengruppe: Pfizer; 2013. Im Internet: http://www.sgar-ssar.ch/fileadmin/user_upload/Dokumente/Infos_zu_Medis/Apixaban_Guideline_d_140115.pdf Stand: 20.02.2017